Midtrimester amniocentesis causes fatal complications in only six out of 10,000 fetuses (0.06%), not five out of 1,000 (0.5%), the oft-quoted CDC statistic, according to a new study.
Midtrimester amniocentesis causes fatal complications in only six out of 10,000 fetuses (0.06%), not five out of 1,000 (0.5%), the oft-quoted CDC statistic, according to a new study.
The new figure is based on a prospective study of 35,000 unselected women with viable singleton pregnancies enrolled in the First and Second Trimester Evaluation of Risk for Aneuploidy trial and is not significantly different from the rate of fetal loss among women not undergoing the procedure. In the study, the rate of spontaneous fetal loss at less than 24 weeks' gestation in the study group was 1.0% and in the control group was 0.94% (P=0.74). In other words, women receiving the procedure were 1.1 times as likely to have a spontaneous loss as women not undergoing the procedure.
According to the authors of the new study, the old, traditionally quoted figure was derived from three nationally sponsored unrandomized studies in the US, Canada, and Great Britain performed in the 1970s when ultrasound was not routine and was drastically inferior in quality to that available today. Also, according to the authors, routinely offering amniocentesis to every woman over the age of 35 is "arbitrary and archaic" and "should be abandoned for a more customized risk assessment."
Commentary from Sharon T. Phelan, MD, Professor, Department of Obstetrics and Gynecology, University of New Mexico, Albuquerque, N.M.:
Most obstetricians have always suspected that in experienced hands the often quoted loss rate of 0.5% was excessive; but it did make the recommendation of genetic screening at age 35 more sensible. This lower risk determination potentially opens up the ability to offer genetic screening to younger women. However, just because a test can be done does not mean it should be done. There needs to be an indication or a specific question to answer, not simply "Is my baby normal?" Patients also need to understand that genetic amniocentesis is not a guarantee that they will have a normal, perfect Gerber's baby.
Personalized opioid protocol for cesarean deliveries: Reduced prescriptions reported
April 19th 2024A recent suggests that implementing a personalized opioid prescription protocol significantly reduces total morphine milligram equivalents and the number of opioid tablets prescribed at discharge following cesarean delivery.
Read More
Gender discrepancy found in ABCA4-associated retinopathy
April 18th 2024A recent meta-analysis suggests sex as a modifying factor in the development of ABCA4-associated retinopathy, revealing a higher proportion of women among individuals with a mild reduced penetrant ABCA4 variant, impacting prognosis predictions and recurrence risks.
Read More
Genetics associated with reproductive traits and uterine leiomyomata
April 17th 2024Investigating genetic correlations and shared loci sheds light on potential causal relationships between reproductive traits and uterine leiomyomata, offering insights into their complex interplay and urging further mechanistic exploration.
Read More